Filing identity and reporting period
Important identity mismatch: The supplied filing is Aquinox Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 12, 2018. It is not a Neurogene Inc. filing. The summary below reflects the filing text provided.
Aquinox was a clinical-stage pharmaceutical company developing rosiptor, a SHIP1 activator, primarily for interstitial cystitis/bladder pain syndrome (IC/BPS). It had no approved products and no revenue.
Financial performance and liquidity
| Metric (US$ millions, except per-share data) | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | None | None | — |
| Research and development expense | 36.3 | 28.4 | +27.8% |
| General and administrative expense | 14.9 | 9.3 | +60.3% |
| Total operating expenses | 51.1 | 37.6 | +35.8% |
| Net loss | (50.2) | (37.0) | Loss increased 35.6% |
| Basic and diluted loss per share | (2.14) | (1.96) | Greater loss per share |
| Cash, cash equivalents and short-term investments | 108.1 | 103.1 | +5.0 |
| Working capital | 97.9 | 94.0 | +4.2 |
Cash used in operating activities was $44.7 million, versus $30.2 million in 2016. Investing activities provided $64.0 million, mainly from investment maturities; financing activities provided $0.4 million, primarily from option exercises. The company reported an accumulated deficit of $198.5 million. Management said existing capital resources were expected to fund operations for at least 12 months, while also anticipating substantial future financing needs.
Total liabilities were $11.4 million, including $11.0 million of current liabilities. The balance sheet shows no conventional borrowings; capital lease obligations were $49,000 net of interest. Contractual lease payments totaled $2.0 million, with $0.9 million due in 2018. No off-balance-sheet arrangements were reported. With no revenue, operating or profit margins are not meaningful.
For the fourth quarter of 2017, operating expenses were $16.5 million and net loss was $16.3 million, compared with $11.5 million and $11.2 million, respectively, in fourth-quarter 2016.
Material changes and business developments
- R&D spending rose as the company advanced the Phase 3 Leadership 301 trial. G&A growth reflected higher personnel costs and pre-commercial and market-assessment work.
- Leadership 301 enrolled 433 participants (341 women and 92 men); enrollment completed in February 2018. The primary endpoint measures change in maximum daily bladder pain at week 12 in female participants. Top-line results were anticipated in the third quarter of 2018.
- The company planned a roughly 100-participant Phase 2 trial of rosiptor for chronic prostatitis/chronic pelvic pain syndrome, with enrollment expected to begin in Q2 2018.
- Cash and investments increased modestly, but operating cash use accelerated. Unlike 2016, when a public offering raised $70.7 million net, 2017 financing cash flow was limited to option exercises.
Outlook, risks and unusual items
- Management expected operating losses and R&D spending to continue rising. FDA and other regulator discussions, along with Leadership 301 results, would inform the number, design and size of any additional trials; more or longer trials could raise costs and delay an NDA.
- Clinical evidence remains uncertain: the Phase 2 Leadership 201 IC/BPS trial missed its primary endpoint for statistical significance (p=0.061), despite favorable secondary endpoints. Separate Phase 2 trials in COPD and atopic dermatitis did not demonstrate efficacy.
- Rosiptor was generally tolerated in prior studies, but gastrointestinal events were common. Animal studies reported severe gastrointestinal ulcerations in dogs and ocular-lens effects; the filing cautions these could pose human safety risks.
- The company depended on third-party manufacturers, including a single-source API manufacturer, and had no identified alternate suppliers. Manufacturing scale-up, quality compliance and supply continuity could affect development or commercialization.
- Other key risks include the unvalidated SHIP1 target, regulatory approval and reimbursement uncertainty, competition, patent protection, foreign-exchange exposure, and the need for additional capital. Rosiptor patents were described as expiring in 2024 in Europe and 2024–2028 in the U.S., before any potential extensions.
- A $2.3 million reduction in deferred tax assets associated with the 2017 U.S. Tax Cuts and Jobs Act was fully offset by a valuation-allowance reduction. The company recorded no income-tax recovery.
Most important facts for investors to verify
- Confirm the issuer and filing: this document is Aquinox’s 2017 10-K, not Neurogene’s.
- Check Leadership 301 top-line results and subsequent regulatory guidance, including whether additional pivotal or safety-exposure trials are required.
- Assess actual cash burn against the stated minimum 12-month runway and the timing and terms of future financing.
- Review the full clinical safety data, especially gastrointestinal and ocular findings, and whether any signals emerged in later or longer-duration exposure.
- Verify manufacturing scale-up plans, backup supply arrangements, patent coverage and remaining exclusivity.